PhD Scientific Days 2026

Poster Session 3.J - Theoretical and Translational Medicine

Exploring Anti-tumor Effect of GSK3β Inhibitor Elraglusib (9-ING-41) on Cancer: Systematic Review of In vivo Studies

Előadó neve

Mr. Ahmed, Ebsa Tofik

Neptune code

Y0CUSC

Előadó munkahelye

Clinical Pathophysiology

Előadó telefonszáma

+36204536025

Előadó e-mail címe

ebsa.ahmed@phd.semmelweis.hu

Az előadás címe

Exploring Anti-tumor Effect of GSK3β Inhibitor Elraglusib (9-ING-41) on Cancer: Systematic Review of In vivo Studies

Szerző(k) neve és munkahelye

Ebsa Tofik Ahmed¹, Csaba Andras Schvarcz, Qusay O. Abdalla, Evan Santo, Daniel Bosci, Zoltan Koos, Hakim Bahlok Jebur, Mohamed I . Elsalahaty, Mingming He, Yibo Gu, Cedrik Kintscher, Peter Hamar¹

1: Semmelweis University

Bemutatás módja

Poszter

Szekció

Poster Session 3.J - Theoretical and Translational Medicine

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Background
Glycogen synthase kinase-3β (GSK3β) plays an important role in the pathogenesis of different types of cancer. Therefore, it is becoming an emerging therapeutic target in many types of cancer. Even though there are many small molecule inhibitors designed against GSK3β, lack of selectivity to GSK3β prevented many promising GSK3β inhibitors from progress in clinical trial phases. Several studies reported 9-ING-41 as a novel and more selective inhibitor of GSK3β in different types of cancer.
Aim
To explore the in vivo antitumor effect of 9-ING-41 either alone or in combination with other drugs on different types of cancer from published studies.
Methods
A systematic literature search was performed in Embase, Pubmed, Scopus and Web of Science databases for papers published during 10 years prior to April 2026. All in vivo studies assessing the anti-tumor effect of 9-ING-41 on different tumor models were included. The primary outcomes such as tumor volume and tumor weight were included. Quality assessment and narrative synthesis of the studies were performed.
Results
Seven studies met eligibility criteria for inclusion out of the 212 papers that were initially identified. Only one included study using the breast cancer tumor model (BC-2 PDX) showed a significant reduction in tumor volume and tumor weight when using the 9-ING-41 therapy alone. However, 9-ING-41 in combination with chemotherapeutic drugs, immune checkpoint inhibitor, and oncolytic adenovirus significantly reduced tumor volume and tumor weight in tumor models such as pancreatic (PCF379419, 6741 PDX), breast (BC-1 PDX, BC-2 PDX), glioblastoma (GBM6 PDX), and neuroblastoma (SK-N-BE, SK-N-DZ) in four included studies.
Conclusion
The 9-ING-41 showed better antitumor effect when used in combination with other therapeutic agents such as chemotherapeutic drugs, immune checkpoint inhibitor and oncolytic adenovirus than when it used alone. Therefore, this review may serve as a baseline line for future research on combination of 9-ING-41 with other therapeutic agents like adjuvant or supplementary therapy in other cancer models.
Funding : SE 250+ Excellence PhD Scholarship
Email: ebsa.ahmed@phd.semmelweis.hu
University: Semmelweis University
Supervisor: Prof. Dr. Peter Hamar
Presentation: Poster Presentation

University

Semmelweis University

Supervisor

Prof. Dr. Peter Hamar

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9741

Start

13:48

End

13:51